Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus

In the absence of an effective vaccine, there is an urgent need for safe and effective antiviral agents to prevent transmission of HIV. Here, we report that an amphipathic α-helical peptide derived from the hepatitis C virus NS5A anchor domain (designated C5A in this article) that has been shown to...

Full description

Saved in:
Bibliographic Details
Published in:Proceedings of the National Academy of Sciences - PNAS 2008-04, Vol.105 (14), p.5525-5530
Main Authors: Bobardt, Michael D, Cheng, Guofeng, de Witte, Lot, Selvarajah, Suganya, Chatterji, Udayan, Sanders-Beer, Brigitte E, Geijtenbeek, Teunis B.H, Chisari, Francis V, Gallay, Philippe A
Format: Article
Language:English
Subjects:
Antivirals
Biological Sciences
CD4-Positive T-Lymphocytes - virology
Cells, Cultured
Dendritic cells
Dendritic Cells - virology
Disease prevention
Disease transmission
Epithelial cells
Hepacivirus - chemistry
Hepatitis
Hepatitis C
Hepatitis C virus
Hepatology
HIV
HIV - drug effects
HIV 1
HIV infections
HIV Infections - prevention & control
Human immunodeficiency virus
Humans
Infections
Liver
Macrophages - virology
Peptide Fragments - pharmacology
Peptide Fragments - therapeutic use
T lymphocytes
Vaccines
Viral Nonstructural Proteins - chemistry
Viral Nonstructural Proteins - pharmacology
Viral Nonstructural Proteins - therapeutic use
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the absence of an effective vaccine, there is an urgent need for safe and effective antiviral agents to prevent transmission of HIV. Here, we report that an amphipathic α-helical peptide derived from the hepatitis C virus NS5A anchor domain (designated C5A in this article) that has been shown to be virocidal for the hepatitis C virus (HCV) also has potent antiviral activity against HIV. C5A exhibits a broad range of antiviral activity against HIV isolates, and it prevents infection of the three in vivo targets of HIV: CD4⁺ T lymphocytes, macrophages, and dendritic cells by disrupting the integrity of the viral membrane and capsid core while preserving the integrity of host membranes. C5A can interrupt an ongoing T cell infection, and it can prevent transmigration of HIV through primary genital epithelial cells, infection of mucosal target cells and transfer from dendritic cells to T cells ex vivo, justifying future experiments to determine whether C5A can prevent HIV transmission in vivo.
ISSN:0027-8424
1091-6490
DOI:10.1073/pnas.0801388105